{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:03:20Z","timestamp":1784685800819,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473302"],"award-info":[{"award-number":["82473302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473303"],"award-info":[{"award-number":["82473303"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04430-y","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:43:49Z","timestamp":1779464629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GFI1 enhances MHC-I expression in tumor cells and augments tumor responsiveness to PD-1\/PD-L1 inhibitors"],"prefix":"10.1007","volume":"75","author":[{"given":"Yu","family":"Xi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ounan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangning","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lequn","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"4430_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa2502931","volume":"393","author":"PM Forde","year":"2025","unstructured":"Forde PM, Spicer JD, Provencio M et al (2025) Overall survival with neoadjuvant Nivolumab plus chemotherapy in lung cancer. N Engl J Med 393:741\u2013752. https:\/\/doi.org\/10.1056\/NEJMoa2502931","journal-title":"N Engl J Med"},{"key":"4430_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jtho.2024.09.1439","volume":"20","author":"S Peters","year":"2025","unstructured":"Peters S, Paz-Ares LG, Reck M et al (2025) Long-term survival outcomes with first-line Nivolumab plus Ipilimumab-based treatment in patients with metastatic NSCLC and tumor Programmed Death-Ligand 1 lower than 1%: a pooled analysis. J Thorac Oncol 20:94\u2013108. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1439","journal-title":"J Thorac Oncol"},{"key":"4430_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004440","author":"M Lopez de Rodas","year":"2022","unstructured":"Lopez de Rodas M, Nagineni V, Ravi A et al (2022) Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004440","journal-title":"J Immunother Cancer"},{"key":"4430_CR4","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41467-018-05032-8","volume":"9","author":"SN Gettinger","year":"2018","unstructured":"Gettinger SN, Choi J, Mani N et al (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196. https:\/\/doi.org\/10.1038\/s41467-018-05032-8","journal-title":"Nat Commun"},{"key":"4430_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/14737140.2023.2208351","volume":"23","author":"QM Zheng","year":"2023","unstructured":"Zheng QM, Li YY, Wang YP, Li GX, Zhao MM, Sun ZG (2023) Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1\/PD-L1 inhibitors: a systematic review and meta-analysis. Expert Rev Anticancer Ther 23:643\u2013659. https:\/\/doi.org\/10.1080\/14737140.2023.2208351","journal-title":"Expert Rev Anticancer Ther"},{"key":"4430_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 52:17\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.011","journal-title":"Immunity"},{"key":"4430_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18:197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y","journal-title":"Nat Rev Drug Discov"},{"key":"4430_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.20517\/cdr.2025.14","volume":"8","author":"J Yu","year":"2025","unstructured":"Yu J, Kong X, Feng Y (2025) Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for cold-to-hot tumor transformation. Cancer drug resistance (Alhambra, Calif) 8:21. https:\/\/doi.org\/10.20517\/cdr.2025.14","journal-title":"Cancer drug resistance (Alhambra, Calif)"},{"key":"4430_CR9","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1038\/s41467-025-59784-1","volume":"16","author":"OA Ojo","year":"2025","unstructured":"Ojo OA, Shen H, Ingram JT, Bonner JA, Welner RS, Lacaud G, Zajac AJ, Shi LZ (2025) Gfi1 controls the formation of effector-like CD8(+) T cells during chronic infection and cancer. Nat Commun 16:4542. https:\/\/doi.org\/10.1038\/s41467-025-59784-1","journal-title":"Nat Commun"},{"key":"4430_CR10","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/leu.2010.195","volume":"24","author":"LT van der Meer","year":"2010","unstructured":"van der Meer LT, Jansen JH, van der Reijden BA (2010) Gfi1 and Gfi1b: key regulators of hematopoiesis. Leukemia 24:1834\u20131843. https:\/\/doi.org\/10.1038\/leu.2010.195","journal-title":"Leukemia"},{"key":"4430_CR11","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2015-06-655043","volume":"126","author":"T M\u00f6r\u00f6y","year":"2015","unstructured":"M\u00f6r\u00f6y T, Vassen L, Wilkes B, Khandanpour C (2015) From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation. Blood 126:2561\u20132569. https:\/\/doi.org\/10.1182\/blood-2015-06-655043","journal-title":"Blood"},{"key":"4430_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.molcel.2007.06.039","volume":"27","author":"S Saleque","year":"2007","unstructured":"Saleque S, Kim J, Rooke HM, Orkin SH (2007) Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell 27:562\u2013572. https:\/\/doi.org\/10.1016\/j.molcel.2007.06.039","journal-title":"Mol Cell"},{"key":"4430_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1182\/blood-2011-10-386094","volume":"120","author":"C Lancrin","year":"2012","unstructured":"Lancrin C, Mazan M, Stefanska M et al (2012) GFI1 and GFI1B control the loss of endothelial identity of hemogenic endothelium during hematopoietic commitment. Blood 120:314\u2013322. https:\/\/doi.org\/10.1182\/blood-2011-10-386094","journal-title":"Blood"},{"key":"4430_CR14","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1158\/0008-5472.Can-18-4032","volume":"79","author":"X Kuai","year":"2019","unstructured":"Kuai X, Li L, Chen R et al (2019) SCF(FBXW7)\/GSK3\u03b2-mediated GFI1 degradation suppresses proliferation of Gastric Cancer cells. Cancer Res 79:4387\u20134398. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-4032","journal-title":"Cancer Res"},{"key":"4430_CR15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/1541-7786.Mcr-18-0666","volume":"17","author":"MS Chen","year":"2019","unstructured":"Chen MS, Lo YH, Chen X et al (2019) Growth Factor-Independent 1 is a tumor suppressor gene in Colorectal Cancer. Mol Cancer Res 17:697\u2013708. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-18-0666","journal-title":"Mol Cancer Res"},{"key":"4430_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134687","author":"N Ashour","year":"2020","unstructured":"Ashour N, Angulo JC, Gonz\u00e1lez-Corpas A, Orea MJ, Lobo MVT, Colomer R, Col\u00e1s B, Esteller M, Ropero S (2020) Epigenetic regulation of Gfi1 in Endocrine-Related Cancers: a role regulating tumor growth. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21134687","journal-title":"Int J Mol Sci"},{"key":"4430_CR17","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1016\/j.celrep.2017.02.073","volume":"18","author":"BT Vo","year":"2017","unstructured":"Vo BT, Li C, Morgan MA et al (2017) Inactivation of Ezh2 upregulates Gfi1 and drives aggressive Myc-driven Group 3 Medulloblastoma. Cell Rep 18:2907\u20132917. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.073","journal-title":"Cell Rep"},{"key":"4430_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41556-021-00672-3","volume":"23","author":"G Li","year":"2021","unstructured":"Li G, Kryczek I, Nam J et al (2021) LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol 23:526\u2013537. https:\/\/doi.org\/10.1038\/s41556-021-00672-3","journal-title":"Nat Cell Biol"},{"key":"4430_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","volume":"42","author":"HN Bell","year":"2024","unstructured":"Bell HN, Zou W (2024) Beyond the barrier: unraveling the mechanisms of immunotherapy resistance. Annu Rev Immunol 42:521\u2013550. https:\/\/doi.org\/10.1146\/annurev-immunol-101819-024752","journal-title":"Annu Rev Immunol"},{"key":"4430_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/08830180902978120","volume":"28","author":"F Zhou","year":"2009","unstructured":"Zhou F (2009) Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 28:239\u2013260. https:\/\/doi.org\/10.1080\/08830180902978120","journal-title":"Int Rev Immunol"},{"key":"4430_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jdiacomp.2016.08.001","volume":"31","author":"LR Filgueiras","year":"2017","unstructured":"Filgueiras LR, Brandt SL, Ramalho TR, Jancar S, Serezani CH (2017) Imbalance between HDAC and HAT activities drives aberrant STAT1\/MyD88 expression in macrophages from type 1 diabetic mice. J Diabetes Complications 31:334\u2013339. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.08.001","journal-title":"J Diabetes Complications"},{"key":"4430_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1756-8935-3-16","volume":"3","author":"LJ Buro","year":"2010","unstructured":"Buro LJ, Chipumuro E, Henriksen MA (2010) Menin and RNF20 recruitment is associated with dynamic histone modifications that regulate signal transducer and activator of transcription 1 (STAT1)-activated transcription of the interferon regulatory factor 1 gene (IRF1). Epigenetics Chromatin 3:16. https:\/\/doi.org\/10.1186\/1756-8935-3-16","journal-title":"Epigenetics Chromatin"},{"key":"4430_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13046-024-03070-3","volume":"43","author":"F Xiong","year":"2024","unstructured":"Xiong F, Wang D, Xiong W et al (2024) Unveiling the role of HP1\u03b1-HDAC1-STAT1 axis as a therapeutic target for HP1\u03b1-positive intrahepatic cholangiocarcinoma. J Exp Clin Cancer Res 43:152. https:\/\/doi.org\/10.1186\/s13046-024-03070-3","journal-title":"J Exp Clin Cancer Res"},{"key":"4430_CR24","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.1128\/mcb.25.23.10338-10351.2005","volume":"25","author":"Z Duan","year":"2005","unstructured":"Duan Z, Zarebski A, Montoya-Durango D, Grimes HL, Horwitz M (2005) Gfi1 coordinates epigenetic repression of p21Cip\/WAF1 by recruitment of histone lysine methyltransferase G9a and histone deacetylase 1. Mol Cell Biol 25:10338\u201310351. https:\/\/doi.org\/10.1128\/mcb.25.23.10338-10351.2005","journal-title":"Mol Cell Biol"},{"key":"4430_CR25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/jcb.10548","volume":"89","author":"L McGhee","year":"2003","unstructured":"McGhee L, Bryan J, Elliott L, Grimes HL, Kazanjian A, Davis JN, Meyers S (2003) Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism. J Cell Biochem 89:1005\u20131018. https:\/\/doi.org\/10.1002\/jcb.10548","journal-title":"J Cell Biochem"},{"key":"4430_CR26","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1016\/j.celrep.2018.03.012","volume":"22","author":"A Maiques-Diaz","year":"2018","unstructured":"Maiques-Diaz A, Spencer GJ, Lynch JT et al (2018) Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia. Cell Rep 22:3641\u20133659. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.012","journal-title":"Cell Rep"},{"key":"4430_CR27","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1096\/fj.11-193706","volume":"26","author":"S Kahali","year":"2012","unstructured":"Kahali S, Sarcar B, Prabhu A, Seto E, Chinnaiyan P (2012) Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. FASEB J 26:2437\u20132445. https:\/\/doi.org\/10.1096\/fj.11-193706","journal-title":"FASEB J"},{"key":"4430_CR28","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1523\/jneurosci.3000-16.2017","volume":"37","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Vidaurre OG, Adula KP, Kezunovic N, Wentling M, Huntley GW, Casaccia P (2017) Subcellular distribution of HDAC1 in neurotoxic conditions is dependent on serine phosphorylation. J Neurosci 37:7547\u20137559. https:\/\/doi.org\/10.1523\/jneurosci.3000-16.2017","journal-title":"J Neurosci"},{"key":"4430_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nn.2471","volume":"13","author":"JY Kim","year":"2010","unstructured":"Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, Casaccia P (2010) HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 13:180\u2013189. https:\/\/doi.org\/10.1038\/nn.2471","journal-title":"Nat Neurosci"},{"key":"4430_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41419-021-03697-6","volume":"12","author":"S Bahl","year":"2021","unstructured":"Bahl S, Ling H, Acharige NPN, Santos-Barriopedro I, Pflum MKH, Seto E (2021) EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function. Cell Death Dis 12:469. https:\/\/doi.org\/10.1038\/s41419-021-03697-6","journal-title":"Cell Death Dis"},{"key":"4430_CR31","doi-asserted-by":"publisher","first-page":"e1004136","DOI":"10.1371\/journal.ppat.1004136","volume":"10","author":"G Sourvinos","year":"2014","unstructured":"Sourvinos G, Morou A, Sanidas I, Codruta I, Ezell SA, Doxaki C, Kampranis SC, Kottakis F, Tsichlis PN (2014) The downregulation of GFI1 by the EZH2-NDY1\/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection. PLoS Pathog 10:e1004136. https:\/\/doi.org\/10.1371\/journal.ppat.1004136","journal-title":"PLoS Pathog"},{"key":"4430_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.molcel.2017.12.024","volume":"69","author":"L Wan","year":"2018","unstructured":"Wan L, Xu K, Wei Y et al (2018) Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. Mol Cell 69:279\u201391.e5. https:\/\/doi.org\/10.1016\/j.molcel.2017.12.024","journal-title":"Mol Cell"},{"key":"4430_CR33","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/jco.23.00580","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti B, Lamberti G, Puchala SR et al (2024) Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer. J Clin Oncol 42:1311\u20131321. https:\/\/doi.org\/10.1200\/jco.23.00580","journal-title":"J Clin Oncol"},{"key":"4430_CR34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2326-6066.Cir-20-0586","volume":"10","author":"M Karasarides","year":"2022","unstructured":"Karasarides M, Cogdill AP, Robbins PB et al (2022) Hallmarks of resistance to immune-checkpoint inhibitors. Cancer Immunol Res 10:372\u2013383. https:\/\/doi.org\/10.1158\/2326-6066.Cir-20-0586","journal-title":"Cancer Immunol Res"},{"key":"4430_CR35","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, Morris LGT, Grigg CM et al (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359:582\u2013587. https:\/\/doi.org\/10.1126\/science.aao4572","journal-title":"Science"},{"key":"4430_CR36","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/2159-8290.Cd-21-0980","volume":"12","author":"V Gambacorta","year":"2022","unstructured":"Gambacorta V, Beretta S, Ciccimarra M et al (2022) Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse. Cancer Discov 12:1449\u20131461. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0980","journal-title":"Cancer Discov"},{"key":"4430_CR37","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1158\/1078-0432.Ccr-17-2483","volume":"24","author":"L Huang","year":"2018","unstructured":"Huang L, Malu S, McKenzie JA et al (2018) The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res 24:3366\u20133376. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2483","journal-title":"Clin Cancer Res"},{"key":"4430_CR38","doi-asserted-by":"publisher","first-page":"32056","DOI":"10.1074\/jbc.M802320200","volume":"283","author":"DE Montoya-Durango","year":"2008","unstructured":"Montoya-Durango DE, Velu CS, Kazanjian A, Rojas ME, Jay CM, Longmore GD, Grimes HL (2008) Ajuba functions as a histone deacetylase-dependent co-repressor for autoregulation of the growth factor-independent-1 transcription factor. J Biol Chem 283:32056\u201332065. https:\/\/doi.org\/10.1074\/jbc.M802320200","journal-title":"J Biol Chem"},{"key":"4430_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci149551","author":"H Wang","year":"2022","unstructured":"Wang H, Lin Z, Nian Z et al (2022) Hematopoietic transcription factor GFI1 promotes anchorage independence by sustaining ERK activity in cancer cells. J Clin Investig. https:\/\/doi.org\/10.1172\/jci149551","journal-title":"J Clin Investig"},{"key":"4430_CR40","doi-asserted-by":"publisher","first-page":"582370","DOI":"10.3389\/fcell.2020.582370","volume":"8","author":"H Mamdani","year":"2020","unstructured":"Mamdani H, Jalal SI (2020) Histone deacetylase inhibition in non-small cell lung cancer: hype or hope? Front Cell Dev Biol 8:582370. https:\/\/doi.org\/10.3389\/fcell.2020.582370","journal-title":"Front Cell Dev Biol"},{"key":"4430_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13402-024-00989-9","volume":"48","author":"W Dong","year":"2025","unstructured":"Dong W, He B, Cao Y et al (2025) Low-dose SAHA enhances CD8(+) T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancer. Cell Oncol (Dordrecht, Netherlands) 48:249\u2013264. https:\/\/doi.org\/10.1007\/s13402-024-00989-9","journal-title":"Cell Oncol (Dordrecht, Netherlands)"},{"key":"4430_CR42","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/1535-7163.Mct-07-2140","volume":"7","author":"A Miyanaga","year":"2008","unstructured":"Miyanaga A, Gemma A, Noro R et al (2008) Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 7:1923\u20131930. https:\/\/doi.org\/10.1158\/1535-7163.Mct-07-2140","journal-title":"Mol Cancer Ther"},{"key":"4430_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010077","author":"T Xu","year":"2024","unstructured":"Xu T, Fang Y, Gu Y et al (2024) HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1\/JAK1\/FGL1 axis in lung adenocarcinoma. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-010077","journal-title":"J Immunother Cancer"},{"key":"4430_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/1078-0432.Ccr-21-2049","volume":"28","author":"Y Gao","year":"2022","unstructured":"Gao Y, P\u00e4ivinen P, Tripathi S et al (2022) Inactivation of AMPK leads to attenuation of antigen presentation and immune evasion in lung adenocarcinoma. Clin Cancer Res 28:227\u2013237. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-2049","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04430-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:53:16Z","timestamp":1784685196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04430-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4430"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04430-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The collection and use of human lung tumor tissue samples were conducted in accordance with the Declaration of Helsinki and were approved by the Institutional Ethics Committee of Huazhong University of Science and Technology (No. 20240367). All animal experiments were approved by the Laboratory Animals Welfare and Ethics Committee of Tongji Hospital (TJH-202408075).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"195"}}